

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

| | | |
|---|--|---|
| 1. Name and Address of Reporting Person* <u>Silva Paul M</u> (Last) (First) (Middle) <u>C/O VERTEX PHARMACEUTICALS INCORPORATED</u> <u>50 NORTHERN AVENUE</u> (Street) <u>BOSTON MA 02210</u> (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC / MA [VRTX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP & Corp Controller</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) <u>05/04/2015</u> | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |
| 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|----------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 05/04/2015 | | M | | 1,125 | A | \$37.86 | 19,500 | D | |
| Common Stock | 05/04/2015 | | S ⁽¹⁾ | | 577 | D | \$126.15 ⁽²⁾⁽³⁾ | 18,923 | D | |
| Common Stock | 05/04/2015 | | S ⁽¹⁾ | | 332 | D | \$127.09 ⁽³⁾⁽⁴⁾ | 18,591 | D | |
| Common Stock | 05/04/2015 | | S ⁽¹⁾ | | 216 | D | \$128.22 ⁽³⁾⁽⁵⁾ | 18,375 | D | |
| Common Stock | 05/05/2015 | | M | | 1,687 | A | \$45.11 | 20,062 | D | |
| Common Stock | 05/05/2015 | | M | | 1,289 | A | \$77.31 | 21,351 | D | |
| Common Stock | 05/05/2015 | | S ⁽¹⁾ | | 1,676 | D | \$121.92 ⁽³⁾⁽⁶⁾ | 19,675 | D | |
| Common Stock | 05/05/2015 | | S ⁽¹⁾ | | 1,000 | D | \$122.9 ⁽³⁾⁽⁷⁾ | 18,675 | D | |
| Common Stock | 05/05/2015 | | S ⁽¹⁾ | | 200 | D | \$123.85 ⁽³⁾⁽⁸⁾ | 18,475 | D | |
| Common Stock | 05/05/2015 | | S ⁽¹⁾ | | 100 | D | \$125.2 | 18,375 | D | |
| Common Stock | | | | | | | | 169 | I | 401(k) |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (right to buy) | \$37.86 | 05/04/2015 | | M | | 1,125 | | (9) | 02/01/2022 | Common Stock | 1,125 | \$0.00 | 3,375 | D | |
| Stock Option (right to buy) | \$45.11 | 05/05/2015 | | M | | 1,687 | | (10) | 02/04/2023 | Common Stock | 1,687 | \$0.00 | 11,813 | D | |
| Stock Option (right to buy) | \$77.31 | 05/05/2015 | | M | | 1,289 | | (11) | 02/04/2024 | Common Stock | 1,289 | \$0.00 | 14,179 | D | |

Explanation of Responses:

- Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of \$126.15 (range \$125.64 to \$126.63).
- Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$127.09 (range \$126.87 to \$127.40).
- Open market sales reported on this line occurred at a weighted average price of \$128.22 (range \$127.99 to \$128.68).

6. Open market sales reported on this line occurred at a weighted average price of \$121.92 (range \$121.56 to \$122.41).
7. Open market sales reported on this line occurred at a weighted average price of \$122.90 (range \$122.58 to \$123.33).
8. Open market sales reported on this line occurred at a weighted average price of \$123.85 (range \$123.68 to \$124.01).
9. The option vests in 16 quarterly installments from 02/02/2012.
10. The option vests in 16 quarterly installments from 02/05/2013.
11. The option vests in 16 quarterly installments from 02/05/2014.

Remarks:

Omar White, Attorney-In-Fact 05/06/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.